Carole L. Nuechterlein's most recent trade in Aligos Therapeutics Inc was a trade of 60,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 27, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Nuechterlein Carole L. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Nuechterlein L. Carole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 4,411 | 4,411 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 11,918 | 11,918 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 23,552 | 23,522 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 2,145,991 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 2,145,991 | 2,145,991 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 662,799 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 662,799 | 2,808,790 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 283,550 | 0 | - | - | Series B-2 Preferred Stock | ||
| Aligos Therapeutics Inc | Carole L. Nuechterlein | Director | 20 Oct 2020 | 283,550 | 3,092,340 | - | - | Common Stock |